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Abstract
Introduction Trivalent influenza vaccines (TIVs) are currently reimbursed for subjects aged ≥ 65 years and children between 
6 and 59 months of age under a national immunization program in South Korea. Quadrivalent influenza vaccines (QIVs) are 
expected to address the potential problem of influenza B-lineage mismatch for TIVs.
Objective The objective of this analysis was to compare the cost effectiveness of QIV versus TIV in children aged 
6–59 months and older adults ≥ 65 years of age in South Korea.
Methods A 1-year static population model was employed to compare the costs and outcomes of a QIV vaccination program 
compared with TIV in children aged 6–59 months and older adults ≥ 65 years of age in South Korea. Influenza-related 
parameters (probabilities, health resource use, and costs) were derived from an analysis of the National Health Insurance 
System claims database between 2010 and 2013 under a broad and narrow set of International Classification of Diseases, 
Tenth Revision (ICD-10) codes used to identify influenza. Other inputs were extracted from published literature. Incremental 
cost-effectiveness ratios (2016 South Korean Won [KRW] per quality-adjusted life-year [QALY] gained) were estimated 
using a ‘limited’ societal perspective as per the Korean pharmacoeconomic guidelines. QALYs lost due to premature mor-
tality were discounted at 5% annually.
Results For both age groups combined, under the narrow definition of influenza, QIV is expected to prevent nearly 16,000 
(2923 in children and 13,011 in older adults) medically attended influenza cases, nearly 8000 (672 in children, 7048 in older 
adults) cases of complications, and over 230 (0 in children, 238 in older adults) deaths annually compared with TIV. The 
impact of using QIV versus TIV in this setting translates into savings of KRW 24 billion (KRW 0.6 billion in children, KRW 
23.4 billion in older adults) in annual medical costs, and over 2100 (18 in children, 2084 in older adults) QALYs. Under the 
broad definition, the corresponding results are over 190,000 (50,697 in children, 140,644 in older adults) influenza cases, 
over 37,000 (12,623 in children, 24,526 in older adults) complications, 270 deaths (0 in children, 270 in older adults), KRW 
94.22 billion (KRW 16 billion in children, KRW 78.2 billion in older adults), and over 3500 QALYs saved (316 in children, 
3260 in older adults).
Conclusion The use of QIV over TIV was estimated to not be cost effective in children 6–59 months of age, but cost saving 
in older adults, using the narrow definition of influenza; however, QIV use was cost saving in both age groups using the 
broad definition. QIV is expected to yield more benefits in older adults ≥ 65 years of age than in children aged 6–59 months 
due to higher influenza-related mortality and costs among the older adults. Further analyses considering the indirect effects 
of influenza vaccination in children are required.
Yun-Kyung Kim and Joon Young Song contributed equally as 
co-first authors.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4027 3-018-0715-5) contains 
supplementary material, which is available to authorized users.
Extended author information available on the last page of the article
1476 Y.-K. Kim et al.
Key Points for Decision Makers 
Influenza is associated with substantial disease burden in 
young children and older adults in South Korea.
This study estimated the impact of a switch from triva-
lent influenza vaccine (TIV) to quadrivalent influenza 
vaccine (QIV) in young children and older adults, using 
data from three influenza seasons.
A switch to QIV is expected to prevent significant 
morbidity and mortality and result in influenza-related 
healthcare cost savings, especially in older adults.
1 Introduction
Influenza is an acute respiratory infection caused by influ-
enza virus. It is estimated that each year 5–10% of adults 
and 20–30% of children worldwide are affected, causing 
substantial morbidity and mortality [1].
Two virus types, namely influenza A and influenza B, are 
responsible for recurrent annual epidemics. They are anti-
genically distinct and do not exhibit cross-immunity, nor do 
they undergo intertypic genetic reassortment (recombina-
tion). Two influenza A subtypes, namely H1N1 and H3N2, 
have co-circulated with influenza B viruses since 1977, and 
current trivalent influenza vaccines (TIVs) contain repre-
sentatives of each A subtype and B virus [2]. The evolution 
of influenza B viruses is characterized by co-circulation of 
antigenically and genetically distinct lineages for extended 
periods of time. Two lineages are defined by phylogenetic 
relationships of hemagglutinin (HA) genes—the ‘B/Victoria 
lineage’ and the ‘B/Yamagata lineage’—and viruses of these 
two lineages have predominated at different times [2].
The World Health Organization’s (WHO) Strategic 
Advisory Group of Experts on Immunization recommends 
(among others) seasonal influenza vaccination for children 
aged 6–59 months, older adults, and those with high-risk 
conditions [1]. Most of the current seasonal influenza vac-
cines are trivalent, containing strains of two influenza A 
subtypes (one of each H1N1 and H3N2) and one strain of 
an influenza B lineage (Victoria or Yamagata), according to 
recommendations of the WHO. However, the incidence of 
influenza B can vary dramatically across influenza seasons. 
In the US, from 2001–2002 through 2010–2011 (excluding 
the 2009–2010 pandemic season), influenza B was respon-
sible for, on average, 24% of influenza-positive samples 
identified during this period (ranging from < 1 to 44%) [3]. 
Based on European surveillance data, influenza B was, on 
average, responsible for 23% of influenza-positive samples 
(ranging from 1 to 60%) [3]. While studies have shown 
similar clinical manifestations and outcomes in adults with 
influenza A and B [4, 5], certain studies have observed an 
increased risk of hospitalization [6] and mortality [7] in chil-
dren with influenza B compared with those with influenza 
A, highlighting, at the very least, the importance of equally 
preventing influenza B.
Furthermore, for trivalent vaccines, antibody responses 
to the lineage not contained in the vaccine are reduced in 
adults and diminished in children [8]. In 5 of the 10 influ-
enza seasons in the US between 2001–2002 and 2010–2011, 
the predominant circulating influenza B lineage was differ-
ent from that chosen for the vaccine [3]. Thus, influenza 
vaccination campaigns with TIVs have had limited effec-
tiveness against influenza B epidemics during seasons in 
which a significant proportion of the disease was caused by 
the mismatched influenza B strain. To address the problem 
of influenza B mismatch, quadrivalent influenza vaccines 
(QIVs) were developed and licensed globally. In addition 
to strains of the two influenza A subtypes, QIVs contain 
strains from both type B lineages (Victoria and Yamagata), 
potentially offering broader protection.
In South Korea, the Korea Centers for Disease Control 
& Prevention (KCDC) recommends annual vaccinations for 
those at high risk. As part of the Korean National Immuniza-
tion Program (NIP), seasonal influenza vaccines are reim-
bursed each year during the flu season for adults ≥ 65 years 
of age, and more recently (for the 2017–2018 flu season) for 
children between 6 and 59 months of age [9]. Only TIV is 
reimbursed in the aforementioned age groups as a part of the 
NIP for the 2017–2018 flu season; QIV can be reimbursed 
in the ≥ 65 years age group on exception (for example, lack 
of TIV) [10]. The vaccination rate in those aged ≥ 65 years 
was 81% in the year 2015–2016  [11] and 73.3% for children 
aged between 1 and 5 years of age [12].
The objective of this study was to determine the cost 
effectiveness of the QIV influenza vaccine compared with 
TIV against seasonal influenza in children aged between 6 
and 59 months and older adults ≥ 65 years of age in Korea 
(Fig. 1).
2  Methods
We performed a title/abstract match PubMed review using 
the search terms ‘Korea’, ‘influenza’, ‘vaccine’ and (‘cost 
effectiveness’ or ‘cost utility’). No cost effectiveness stud-
ies in a South Korean setting for a general population were 
subsequently identified.
2.1  Model Structure
The model employed was a 1-year static decision-tree 
population model developed in Microsoft Excel (2016; 
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Microsoft Corporation, Redmond, WA, USA) assessing 
the cost effectiveness of QIV vaccination strategy against 
seasonal influenza versus TIV strategy (Fig. 2). Details 
regarding the model used have been previously published 
[13] and its validity (structural and conceptual) [14] assessed 
by an internal panel of cross-functional experts (functions 
Focus on the Paent 
What is new? 
What is the context? 
Influenza is associated with substanal disease burden in young children and older adults. Two disnct influenza virus types;  
influenza A (common strains: H1N1 and H3N2) and influenza B (two lineages: B/Yamagata and B/Victoria), are responsible for 
recurrent annual epidemics. Trivalent influenza vaccines (TIVs) contain strains of two influenza A subtypes and one strain of an
influenza B lineage. However, the prevailing influenza B lineage for the current season can be different from the lineage 
present in the vaccine resulng in diminished protecon. To address this problem, quadrivalent influenza vaccines (QIVs) were 
developed. 
As part of the Korean Naonal Immunizaon Program (NIP), TIV is provided each year for older adults and young children. This 
study esmated the impact of a switch from TIV to QIV in the eligible age-groups using data from three influenza seasons. A 
switch to QIV is expected to prevent significant morbidity, mortality and result in influenza-related healthcare cost savings.  
What is the impact? 
Inclusion of QIV as a part of the Korean NIP against seasonal influenza is expected to address the limitaons of TIV. This 
added protecon is significant in older adults where the morbidity and mortality of influenza is highest. 
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Fig. 2  Decision tree used to compare QIV with TIV. QIV quadrivalent influenza vaccine, TIV trivalent influenza vaccine
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including, but not limited to, medical, epidemiology, and 
statistics).
The accumulated costs and outcomes over a 1-year period 
of two age groups (viz 6–59 months and ≥ 65 years) vac-
cinated with QIV were compared with those vaccinated 
with TIV. Since the model only compared the cohorts over 
a 1-year period, no discounting was applied to either costs 
or outcomes; quality-adjusted life-years (QALYs) lost due 
to premature death from an influenza complication were 
discounted at 5% in accordance with the Korean pharmaco-
economic guidelines [15, 16]. In the base-case, the model 
included both costs reimbursed by the National Health Insur-
ance and out-of-pocket expenses incurred by a patient based 
on a ‘limited’ societal perspective as per the Korean pharma-
coeconomic guidelines [17]. Thus, direct non-medical costs 
and indirect costs (for example, productivity losses of the 
individual or caregiver) were not included in the analysis.
2.2  Demographics
The age-specific Korean population [18] estimates for 2016 
were obtained from the Korean Statistical Information 
Service.
2.3  Epidemiology
To determine the incidence of seasonal influenza in Korea, 
a sample cohort of approximately 1 million individuals 
enrolled in the Korean National Health Insurance Service 
(NHIS) was used for analysis. The NHIS consists of two 
major healthcare programs for universal coverage of all 
residents of Korea—National Health Insurance, and Medi-
cal Aid. Approximately 97% of the population is covered 
by National Health Insurance, and the remaining 3% of the 
population is covered by Medical Aid [19].
For the study, a sample cohort from 2010 to 2013 was 
used. Three waves were generated: October 2010–April 
2011; October 2011–April 2012; and October 2012–April 
2013. Based on their age at 15 January 2010, individuals 
were grouped into the following age groups: ≤ 59 months 
and ≥ 65 years.
Based on an evaluation conducted by the National Evi-
dence-based Healthcare Collaborating Agency (NECA) 
[20], seasonal influenza was identified by a set of Interna-
tional Classification of Diseases, Tenth Revision (ICD-10) 
codes mentioned as either a primary or secondary diagno-
sis in the corresponding individual’s claim. Further ICD-10 
codes added to the initial list based on the authors’ clinical 
discretion and two definitions, each with its own code set, 
were arrived at to retrospectively identify influenza from the 
NHIS (electronic supplementary Table 9). The two defini-
tions were expected to represent broad to narrow definitions 
for seasonal influenza. Any diagnosis codes with pathogen 
and without influenza in the description were excluded 
among the aforementioned ICD-10 codes.
The incidence of influenza for each wave was defined as 
the proportion of sample persons identified with influenza 
(ICD-10 codes are presented in electronic supplementary 
Table 9) among the total number of sample persons in each 
age group per wave. The incidence rate was then averaged 
across the three waves. Similarly, the average probability 
of hospitalization was calculated as the proportion of indi-
viduals identified with influenza who used any inpatient ser-
vices with regard to influenza-related complications (ICD-10 
codes are presented in electronic supplementary Table 10) 
among the total number of sample persons in each age group 
for each of the three waves (Table 1).
Table 1  Age-specific 
epidemiological probabilities
Based on the analysis of the National Health Insurance Service database using the International Classifica-
tion of Diseases codes identified by experts and previous publications [20, 21]
a Assumed to be zero in the base-case analysis
6–59 months ≥65 years
Narrow defini-
tion (%)
Broad defini-
tion (%)
Narrow defini-
tion (%)
Broad 
definition 
(%)
Incidence of influenza 4.64 80.41 5.52 59.68
Complications following influenza 22.98 24.90 54.17 17.44
 Being a newly diagnosed complication 99.19 99.26 86.57 83.04
 Complication being an exacerbation 0.81 0.74 13.43 16.96
Case-fatality rates
 Inpatient complications 0.00 0.00 6.48 2.07
 Outpatient complications 0.00 0.00 0.72 0.24
 Non-complicated  influenzaa 0.00 0.00 8.43 0.71
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2.3.1  Influenza‑Related Complications
Complications associated with a case of influenza were cat-
egorized as ‘newly diagnosed complications’ and ‘exacer-
bation of existing chronic diseases’ based on the authors’ 
clinical discretion and a previous analysis on the burden of 
viral respiratory disease in Korea [21]. The definitions of 
the categories are:
• Newly diagnosed complications: Hospitalization or out-
patient visit with defined disease codes within 4 weeks 
after an influenza event and having no defined disease 
codes (inpatient and outpatient) within 1 year before an 
influenza event.
• Exacerbation of existing chronic conditions: Hospitali-
zation with defined disease codes (main codes) within 
4 weeks after an influenza event and having no hospitali-
zation with defined disease codes within 1 year before an 
influenza event.
Based on the ICD-10 codes used to define the corre-
sponding influenza-related complications for the various age 
groups (electronic supplementary Table 10), and the corre-
sponding influenza cases for those age groups, the probabili-
ties of developing complications were estimated (Table 1).
2.3.2  Mortality
The NHIS provides linked death records for the sample 
cohort from the Korean National Statistical Office to inform 
causes of death [22]. Influenza-related mortality was defined 
as any death occurring within 2 months after influenza diag-
nosis, and was estimated for the various influenza outcomes 
(Table 1).
We observed that the mortality ratio for the non-compli-
cated influenza cases in the older adults (≥ 65 years of age) was 
higher than those with complications resulting in hospitaliza-
tion. A possible reason for this observation could be that for 
either of the two earlier-defined complication categories a con-
servative restriction of no hospitalization for the corresponding 
ICD codes for a period of 1 year prior to the current influenza 
diagnosis was applied. In particular, for older individuals with 
chronic medical conditions with frequent hospitalizations, this 
restriction might not take into account ‘true’ influenza-related 
exacerbations (which could potentially be identified through a 
medical chart review). Thus, individuals with cases classified 
as non-complicated based on the complication criteria listed 
earlier might have been misclassified and this might explain 
the reason for the high mortality rates. Hence, for the base-
case analysis, we assumed no mortality for non-complicated 
influenza across all ages.
2.3.3  Influenza Circulation
The proportion of influenza B strains among the overall influ-
enza-positive cases identified each year were obtained from 
the Korean Influenza Surveillance Scheme reports [23]. The 
subsequent breakdown of the influenza B lineages for each 
of those years was obtained from a study that looked at the 
epidemiology of influenza B disease in various Asia–Pacific 
countries [24]. The percentage of influenza B mismatch for 
TIV is calculated as 1 − (percentage of the B-lineage included 
in TIV) that was observed circulating in that corresponding 
year. The 2009–2010 season was excluded due to the predom-
inantly pandemic influenza strain circulation in that season.
The B-lineage distribution was not reported for two seasons, 
i.e. 2008–2009 and 2010–2011. To impute the missing values, 
the average of the other four seasons was assumed. Finally, sim-
ple averages of the TIV influenza B mismatch and the propor-
tion of influenza B circulating over six influenza seasons were 
estimated (Table 2). If weighted for the proportion of B circula-
tion across the six seasons, the weighted average of B-lineage 
mismatch was 73.5%; however, the simple average value was 
used to model a more conservative estimate.
2.4  Costs
We extracted cost data from insurance claims for the afore-
mentioned three waves (October 2010–April 2011; Octo-
ber 2011–April 2012; and October 2012–April 2013) and 
Table 2  Influenza B distribution 
and vaccine B-lineage mismatch 
in Korea
a Imputed values are based on the B-lineage average for other seasons
Year Vaccine lineage Type B (%) Circulating lineage (%) Mismatch (%)
Victoria Yamagata
2007–2008 Victoria 64.1 0.0 100.0 100.0
2008–2009 Yamagata 1.2 55.9a 44.1a 55.9
2010–2011 Victoria 0.9 55.9a 44.1a 44.1
2011–2012 Victoria 48.5 73.0 27.0 27.0
2012–2013 Yamagata 5.6 64.6 35.4 64.6
2013–2014 Yamagata 53.0 86.0 14.0 86.0
Average 28.9 62.9
1480 Y.-K. Kim et al.
adjusted it to 2016 South Korean Won (KRW) using the 
Korean gross domestic product (GDP) deflators [25].
For the cost of inpatient stay, we identified any claims for 
patients who used inpatient services with regard to influ-
enza-related complications (ICD-10 codes are presented in 
electronic supplementary Table 10) and summed the cost per 
patient in order to obtain the mean cost of the inpatient stay 
per person. The cost of outpatient treatment was similarly 
calculated as the cost of inpatient stay, using the cost of the 
outpatient service instead of cost per person.
For each category of complication, the average cost of 
inpatient stay included hospitalization and related medica-
tion costs. The average length of stay (ALoS; in days) was 
estimated based on the length of the inpatient stay for each 
complication per influenza season (Table 3).
In the case of a complication that required only outpatient 
treatment, the average cost was estimated based on the cor-
responding hospital consultation and medication costs. No 
outpatient visits were assumed for complications that were 
exacerbations of existing chronic conditions.
For non-complicated influenza cases (defined as all influ-
enza cases identified without the codes listed in electronic 
supplementary Table 10), the corresponding costs for out-
patient and inpatient services were included.
2.4.1  Vaccine and Antiviral Costs
Vaccine costs were assumed to be KRW 7510 for TIV (based 
on the 2016 NIP procurement price) [26] and KRW 11,265 
for QIV (assuming a 50% premium due to the inclusion of 
an additional B lineage). No administration costs were con-
sidered as the same dosage and coverage was assumed for 
both vaccines.
Antivirals (neuraminidase inhibitors [NIs]) are usually 
prescribed for an influenza event; however, the NHIS only 
reimburses a portion of the costs based on the age and risk 
category of the individual [27, 28]. The antiviral prescrip-
tions and average reimbursed cost per prescription were 
extracted from the NHIS sample cohort. The out-of-pocket 
costs for antivirals were included in the analysis. A price of 
KRW 30,000 was assumed for a 5-day course of antivirals 
(based on the list price in the NHIS for oseltamivir 75 mg, 
5-day course; i.e. 10 tablets per course—KRW 2170 per 
tablet—and a pharmacy preparation cost of KRW 6070; the 
total cost [KRW 27,770] was rounded up to KRW 30,000) 
Table 3  Age-specific direct 
medical costs for influenza-
related outcomes
ALoS average length of stay, KRW South Korean Won
Narrow definition Broad definition
6–59 months ≥ 65 years 6–59 months ≥ 65 years
Newly diagnosed complications
 Probability of hospitalization (%) 28.18 37.83 25.41 36.17
 Mean cost of inpatient stay (KRW) 729,875 4,298,958 760,918 4,303,776
 ALoS (days) 6.95 19.80 7.20 19.46
 Mean cost of outpatient treatment (KRW) 63,633 123,083 66,547 149,819
Exacerbation of existing chronic conditions
 Probability of hospitalization (%) 100 100 100 100
 Mean cost of inpatient stay (KRW) 2,861,959 4,192,447 4,664,615 3,201,406
 ALoS (days) 7.79 31.45 10.62 22.39
 Mean cost of outpatient treatment (KRW) – – – –
Non-complicated influenza cases
 Mean cost of treatment (KRW) 158,127 1,450,271 290,571 232,767
Table 4  Estimated out-of-pocket costs for antivirals
NI neuraminidase inhibitor, OOP out-of-pocket, KRW South Korean Won
6–59 months ≥ 65 years
Narrow definition Broad definition Narrow definition Broad definition
OOP NI costs for non-complicated cases (KRW) 22,276 29,545 29,248 29,916
OOP NI costs for complicated cases (KRW) 24,868 29,720 29,766 29,866
Non-complicated influenza cases (%) 77.02 75.10 45.83 82.56
Complicated influenza cases (%) 22.98 24.90 54.17 17.44
Overall OOP NI costs (KRW) 22,872 29,589 29,529 29,908
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[29]. All individuals seeking treatment for influenza were 
assumed to receive a 5-day course of antivirals [27, 30]. 
Based on the reimbursed costs obtained from the NHIS anal-
ysis, as well as the assumed cost of the antiviral prescription, 
the out-of-pocket costs were estimated for each age group 
(see the ‘Estimation of Out-of-Pocket Antiviral Costs’ sec-
tion in the electronic supplementary material) (Table 4).
2.5  Vaccine Efficacy (VE)
The model incorporates vaccine efficacy (VE) against influ-
enza separately as efficacy against Influenza A and Influenza 
B. For TIV, the efficacy against the latter is broken down as 
efficacy against a B-lineage match and mismatch scenario.
where pA =  % influenza A identified among circulating 
influenza-positive samples identified,  VEA = vaccine effi-
cacy against Influenza A, pB-mismatch = percentage of influ-
enza B identified among circulating influenza B that does not 
match the B-lineage included in the vaccine, and  VEB-mismatch 
= vaccine efficacy against Influenza B for the B-lineage not 
included in the vaccine.
2.5.1  VE Against Influenza A
The reported VEs against influenza can vary depending 
on the study design, outcomes measured, population stud-
ied, and the season in which the flu vaccine was studied. 
To obtain an unbiased estimate of VE for the various age 
Vaccine efficacy, VETIV,overall
= VEA.pA +
(
VEB, mismatch.pB-mismatch
+VEB, match.
(
1 − pB-mismatch
))
.
(
1−pA
)
groups, meta-analyses of randomized controlled trials for 
TIV were used (see the ‘Estimation of Vaccine Efficacies’ 
section in the electronic supplementary material) [31–33]. 
TIV VE against influenza A was assumed to be the same as 
that of the overall VE reported against influenza as neither 
of the meta-analyses in children or older adults assessed effi-
cacy against influenza A separately. Both TIV and QIV con-
tain the same WHO-recommended influenza A strains each 
year. Subsequently, VE against influenza A for both vaccines 
in both age groups was assumed to be the same. A recently 
concluded QIV efficacy trial in children aged 6–35 months 
reported that QIV efficacy against seasonal influenza of any 
severity was 50% [34]. Nonetheless, we assumed the same 
VE for QIV as that estimated for TIV for children between 
6 and 59 months of age.
2.5.2  VE Against Influenza B
VE for TIV against influenza B in adults (18–64 years of 
age) against vaccine-matched (77%) and mismatched (52%) 
influenza B lineages was estimated from a meta-analysis [8].
Since no estimate of TIV efficacy against matched and 
mismatched B lineages were available for children and older 
adults, the relative overall efficacy proportion of TIV against 
influenza relative to adults (as described in Table 5) was 
applied to the efficacies against reported by Tricco et al. [8]. 
Please refer to the ‘Estimation of Vaccine Efficacies’ section 
in the electronic supplementary material for more details.
Due to the static nature of the model, no herd effect was 
incorporated in the model.
VE for QIV against Influenza B is assumed to be the same 
as that of TIV against a matched B-lineage scenario [35].
Table 5  Age-specific vaccine 
efficacy assumptions for 
influenza A and B with TIV or 
QIV
NA not applicable, QIV quadrivalent influenza vaccine, TIV trivalent influenza vaccine, VE vaccine efficacy
a Pooled estimate (using a random-effects model) of outcomes in children < 6 years of age, as reported by 
Jefferson et al. [33]
b Pooled estimate of randomized controlled trials of parenteral vaccine versus placebo in the review by Jef-
ferson et al. [32]
c Proportional estimate obtained by multiplying the ratio of VE (in adults) against influenza B in matched/
mismatched scenarios (as reported by Tricco et al. [8]) and the VE (in adults) against influenza (as reported 
by Demicheli et al. [31]; 63%) with the VE assumed against influenza A for the particular age group (see 
footnote ‘a’ or ‘b’)
d Assumed to be the same as the matched B-lineage scenario for TIV [35]
Age group Vaccine efficacy 
against influenza A
Vaccine efficacy against influenza B
TIV QIV TIV QIV
Matched Mismatched Matched Mismatched
6–59 months 0.47a 0.47a 0.58c 0.39c 0.58d NA
≥ 65 years 0.58b 0.58b 0.72c 0.49c 0.72d NA
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2.5.3  Vaccine Coverage
Yang and Cho reported influenza vaccine coverage of 81.2% 
and 83.1% in the 65–74 years and ≥ 75 years age groups for 
the 2011–2012 influenza season, based on the Korean Com-
munity Health Survey [36]. Adjusting for population sizes, 
the average coverage in the ≥ 65 years age group was cal-
culated to be 82%. A study that assessed the Korea National 
Health and Nutrition Examination Survey estimated that the 
influenza vaccine coverage in children < 5 years of age was 
78.9% in 2014 [37]. Since vaccination was free in this age 
group as a part of the universal mass vaccination program 
from the 2017–2018 season, the same coverage in older 
adults was assumed for the 6–59 months age group.
2.6  Utilities
A disutility of 0.44 was applied for any influenza epi-
sode irrespective of whether the episode was complicated 
or uncomplicated, or if it also required hospitalization or 
resulted in an outpatient visit [38, 39]. To estimate the 
QALY loss for hospitalized complications, the ALoS esti-
mated from the NHIS data sample was used. The overall 
QALY loss for hospitalized complicated influenza cases was 
calculated based on the ALoS weighted for the ratio of newly 
diagnosed complications to exacerbations of chronic condi-
tions for each age group (Table 6). Complicated influenza 
treated in an outpatient setting, as well as non-complicated 
influenza, were assumed to last 5 days irrespective of the 
age of the individual.
To estimate the discounted QALYs lost due to prema-
ture influenza-related death, the age-specific Korean health-
adjusted life expectancies (HALE) for 2011 were used [40]. 
Because HALE was reported for 5-year age groups, a quad-
ratic curve was fitted to the reported data to obtain an esti-
mate for HALE for single-year age groups. Next, for each 
single-year age group, the present value of the HALE was 
estimated using the annuity method discounted at various 
rates, i.e. 0, 3, and 5%. Finally, to estimate the average dis-
counted HALE for each of the aforementioned age groups, 
a population-weighted approach was used (Table 6).
2.7  Sensitivity Analysis
A major parameter that was expected to determine the 
results was the extent of the B-lineage mismatch. To assess 
the impact of the variation in B-mismatch on the cost-effec-
tiveness outcomes, two scenarios were tested:
• Low mismatch: B-mismatch assumed to be 0%.
• High mismatch: B-mismatch assumed to be 100%.
A univariate analysis was performed by varying each 
parameter over the 95% confidence intervals using the 
Table 6  Age-specific QALY 
loss estimates for influenza-
related outcomes
6-59 months ≥ 65 years
Narrow 
definition
Broad 
definition
Narrow 
definition
Broad 
definition
HOSPITALISED CASES
ALoS - Newly diagnosed 
complications 6.95 7.2 19.8 19.46
ALoS - Exacerbations of chronic 
conditions 7.79 10.62 31.45 22.39
QALY loss 0.0084 0.0088 0.0281 0.0248
OUTPATIENT CASES
Duration - Newly diagnosed 
complications 5
QALY loss 0.006
Duration - Non-complicated influenza 5
QALY loss 0.006
Population weighted average HALE (years)
0% Annual discount rates 69.8 10.9
3% Annual discount rates 29.1 9.1
5% Annual discount rates 19.3 8.1
ALoS average length of stay, HALE health-adjusted life expectancies, QALY quality-adjusted life-year
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underlying probability distributions listed in electronic sup-
plementary Table 15. A probabilistic sensitivity analysis 
was performed using a Monte-Carlo simulation of over 2000 
iterations for either of the influenza case definitions. A 99% 
correlation was assumed between vaccine efficacies for TIV 
against vaccine B strain match and mismatch scenarios. The 
rationale for the assumption is that a higher efficacy against 
influenza B in a match scenario should facilitate higher 
protection in the B mismatch scenario and vice versa. The 
approach used to force correlations between these param-
eters has been previously published [41].
3  Results
3.1  Base‑Case Scenario
3.1.1  Narrow Case Definition
In the base-case scenario for children aged 6–59 months, 
the use of QIV over TIV is expected to result in prevent-
ing nearly 3000 cases of influenza and approximately 670 
influenza-related complications annually throughout South 
Korea. The prevented cases result in over KRW 606 million 
in healthcare costs (defined as the sum of hospitalization, 
outpatient, treatment of non-complicated influenza, and 
antiviral costs) and 18 QALYs saved each year. However, 
the incremental cost-effectiveness ratio (ICER) in this age 
group is approximately KRW 345 million per QALY gained, 
compared with a threshold of 1 GDP per capita of KRW 
32,038,000 for the year 2016 [42].
In older adults ≥ 65 years of age, the use of QIV over 
TIV is expected to result in preventing nearly 13,000 cases 
of influenza and approximately 7000 influenza-related com-
plications. The prevented cases result in over KRW 23 bil-
lion in healthcare costs and over 2000 QALYs saved each 
year. The switch to QIV is expected to be cost saving, with 
an incremental saving of KRW 2.6 billion each year. The 
complete incremental outcomes are presented in Table 7.
3.1.2  Broad Case Definition
Using the broader definition, in the base-case scenario for 
children ≤ 59 months of age, the use of QIV over TIV is 
expected to result in preventing nearly 51,000 cases of influ-
enza and approximately 13,000 influenza-related complica-
tions annually. The prevented cases result in over KRW 16 
billion in healthcare costs and over 300 QALYs saved each 
Table 7  Base-case results for the narrow and broad case definitions
All costs are reported in millions of KRW
ICER incremental cost-effectiveness ratio, KRW South Korean Won, NI neuraminidase inhibitors, QALYs quality-adjusted life-years, QIV quad-
rivalent influenza vaccine, TIV trivalent influenza vaccine
a Does not include administration costs
6–59 months ≥ 65 years
Narrow definition Broad definition Narrow definition Broad definition
TIV QIV TIV QIV TIV QIV TIV QIV
Vaccinated 1,830,328 1,830,328 1,830,328 1,830,328 5,545,530 5,545,530 5,545,530 5,545,530
Influenza cases 63,734 60,811 1,105,485 1,054,788 196,400 183,389 2,122,925 1,982,281
Non-complicated cases 49,086 46,835 830,251 792,176 90,011 84,048 1,752,725 1,636,607
Influenza complications 14,648 13,976 275,234 262,611 106,389 99,341 370,200 345,674
  Hospitalizations 4213 4020 71,468 68,190 49,133 45,878 173,991 162,464
  Outpatient 10,435 9957 203,766 194,421 57,256 53,463 196,209 183,211
Influenza deaths 0 0 0 0 3595 3357 4075 3805
Total costs (KRW, millions) 26,956 33,223 363,586 354,416 394,733 392,164 1,222,115 1,164,733
  Hospitalization 3327 3174 62,324 59,466 209,698 195,806 679,603 634,580
  Outpatient 664 634 13,560 12,938 7047 6580 29,396 27,448
  No complications 7762 7406 241,247 230,183 130,541 121,893 407,977 380,949
  NI costs 1458 1391 32,710 31,210 5799 5415 63,492 59,285
  Vaccination  costsa 13,746 20,619 13,746 20,619 41,647 62,470 41,647 62,470
QALYs lost (discounted at 5%) 396 378 6887 6571 31,466 29,382 49,202 45,942
Incremental costs (KRW, millions) 6267 − 9171 − 2568 − 57,382
Incremental QALYs 18 316 2085 3260
ICER (million KRW/QALY gained) 345.4 Cost saving Cost saving Cost saving
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year. The switch from TIV to QIV is expected to be cost sav-
ing in this age group (incremental annual savings of KRW 
9.2 billion).
In older adults aged ≥ 65 years, the use of QIV over TIV 
is expected to result in preventing nearly 140,000 cases 
of influenza and approximately 25,000 influenza-related 
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Fig. 3  Impact of B-lineage mismatch on incremental costs between TIV and QIV (narrow and broad definition). KRW South Korean Won, Low 
B Mismatch B-mismatch assumed to be 0%, High B Mismatch B-mismatch assumed to be 100%
-3.1
-5.8
1,493.0
411.3
3.1
2.6
1.4
2.1
2.1
1.4
1.9
1.8
1.8
1.8
1.8
1.8
1.8
1.8
8,277.7
1,493.0
-5.1
-5.5
0.4
0.9
2.4
1.2
1.3
2.1
1.6
1.7
1.7
1.7
1.7
1.8
1.8
1.8
-500 500 1,500 2,500 3,500 4,500 5,500 6,500 7,500 8,500 9,500
Matching within B - AVERAGE
TIV VE against influenza B in case of mismatch - 65+ yrs
TIV VE against influenza B with matching - 65+ yrs
% circulating influenza B - AVERAGE
Cost of hospitalisation following complication - 65+ yrs
Cost of non-complicated influenza - 65+ yrs
TIV VE against influenza A strains - 6 to 59 mo
QIV VE against influenza A strains - 6 to 59 mo
TIV VE against influenza B with matching - 6 to 59 mo
TIV VE against influenza B in case of mismatch - 6 to 59 mo
Probability to have symptomatic influenza B - 65+ yrs
Cost of outpatient treatment for complication - 65+ yrs
NI medication costs - 65+ yrs
Cost of non-complicated influenza - 6 to 59 mo
Cost of hospitalisation following complication - 6 to 59 mo
Probability to have symptomatic influenza B - 6 to 59 mo
NI medication costs - 6 to 59 mo
Cost of outpatient treatment for complication - 6 to 59 mo
Cost per QALY gained (KRW, millions)
Low estimate High estimate
Fig. 4  One-way sensitivity analyses results for the narrow definition 
for ICER. ICER incremental cost-effectiveness ratio, KRW South 
Korean Won, mo months, NI neuraminidase inhibitor or antiviral, 
QALY quality-adjusted life-year, QIV quadrivalent influenza vaccine, 
TIV trivalent influenza vaccine, VE vaccine efficacy, yrs years
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complications annually. The prevented cases result in over 
KRW 78 billion in healthcare costs and over 3200 QALYs 
saved each year. The switch to QIV is expected to be cost 
saving, with an incremental saving of KRW 57 billion each 
year. The complete incremental outcomes are presented in 
Table 7.
3.2  Variations in B‑Mismatch
In the base-case, the average B-mismatch over the six influ-
enza seasons was used to parameterize the model.
The incremental costs of the switch from TIV to QIV are 
highly sensitive to variations in B strain mismatch, espe-
cially for the ≥ 65 years age group, as can be seen in Fig. 3 
and electronic supplementary Table 16.
3.3  One‑Way Sensitivity Analysis
The results of the one-way sensitivity analysis (in terms 
of ICERs) are presented in Figs. 4 and 5. The parameters 
that have the greatest impact on the incremental costs are 
the relative efficacies of QIV and TIV against influenza A, 
the VE against influenza B for TIV in the mismatch sce-
nario, and the proportion of influenza B circulating in the 
season.
3.4  Probabilistic Sensitivity Analysis
The results of the simulations for both definitions of influenza 
are presented in Fig. 6. As seen in Fig. 7, under the broad defi-
nition, 93.9% and 96.5% of simulations fell below the 1 GDP 
per capita willingness to pay (WTP) threshold for children 
6–59 months of age and older adults aged ≥ 65 years, respec-
tively. Under the narrow definition, 92.4% of simulations were 
under the WTP threshold for older adults, while none of the 
simulations in children fell under the threshold.
4  Discussion
This study assessed the clinical and economic impact of 
switching from the currently reimbursed TIV to QIV for 
two at-risk age groups—children 6–59 months of age and 
older adults aged ≥ 65 years. The burden of influenza over 
three influenza seasons (2010–2013) was estimated using 
a national sample cohort of the Korean NHIS using two 
different influenza definitions—a narrow definition and a 
broader definition.
In the base-case scenario using the narrow case definition, 
the switch to QIV from TIV is estimated to be cost saving 
for the population aged ≥ 65 years, and not cost effective in 
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Fig. 5  One-way sensitivity analyses results for the broad definition 
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children aged ≤ 59 months, based on a threshold of 1 GDP 
per capita for South Korea. However, the switch to QIV was 
estimated to be cost saving for both age groups using the 
broad definition.
The contrasting results for children and older adults using 
the narrow influenza definition despite similar levels of inci-
dence could potentially be explained by four factors:
1. Lower probability of developing complications in chil-
dren (estimated to be approximately 50% lower in chil-
dren).
2. Lower costs of hospitalization (approximately 83% 
lower), outpatient treatment (approximately 50% lower) 
for newly diagnosed complications and non-complicated 
influenza (approximately 90% lower).
3. Lower QALY losses in newly diagnosed complications 
due to the lower ALoS in children (approximately 65% 
lower).
4. No mortality was assumed for children (compared with 
approximately 2% overall in the older adults). A 5% 
mortality in the case of a hospitalized complication in 
children would result in an ICER of KRW 30,734,041 
Fig. 6  Cost-effectiveness plane. 
GDP gross domestic product, 
KRW South Korean Won, QALY 
quality-adjusted life-year, QIV 
quadrivalent influenza vaccine, 
TIV trivalent influenza vaccine
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per QALY gained (electronic supplementary Fig. 9), 
which is almost similar to the WTP threshold of 1 GDP 
per capita.
Similar discrepancies in resource use with regard to hos-
pitalization were also reported in the previous literature. For 
example, Thommes et al. reported a 1.39- to 1.66-fold higher 
hospitalization cost among adults aged 60 years or older 
compared with children < 8 years of age in Canada, and a 
4.33-fold higher hospitalization cost for those aged 65 years 
or older in the UK compared with children < 5 years of age 
[39]. Similarly, a public health assessment of QIV use over 
TIV in Latin America observed that the costs of hospitali-
zation in Brazil in those over 60 years of age was 1.34-fold 
higher than children < 5 years of age (the rate of hospitali-
zation was also 2.46-fold higher in older adults compared 
with children) [43].
As expected, and as evident from the one-way sensitivity 
analyses, the key differentiator between QIV and TIV, i.e. 
the efficacy against influenza B, was seen to drive the results 
of the analysis. The proportion of influenza B circulating 
magnifies the incremental costs and QALYs observed. At the 
same time, the reported proportion of B circulating was seen 
to vary significantly, with three of the six seasons seeing an 
average of 3% of B circulation and the remaining three an 
average of 55%.
Despite the sensitivity of the results to the variance in the 
input parameters, more than 90% of the simulations for both 
age groups, using either the broad or narrow definition of 
influenza, were observed to fall below the WTP threshold of 
1 GDP per capita (except for children using the narrow defi-
nition). This demonstrates the value of a switch from TIV 
to QIV, especially in the case of the older adult age group. It 
has to be noted that, globally, there are no explicit guidelines 
for an ICER threshold for an intervention to be considered 
as cost effective [44, 45]. Rather, threshold values for past 
imbursement decisions are often referred to as experience-
based thresholds for ICER [46, 47]. The pharmacoeconomic 
guidelines for South Korea also do not suggest an explicit 
threshold for ICER, but recommend 1 × GDP per capita as 
the baseline for the threshold, and call for a flexible assess-
ment, taking into consideration disease severity, societal 
burden, impact on quality of life, and innovativeness of the 
drug to be assessed [48, 49].
There are limitations to this analysis, with the primary 
limitation being the accuracy of estimating the incidence of 
influenza from a database of insurance claims using ICD-
10 codes. For example, pneumonia cases diagnosed as only 
a bacterial infection (following a non-medically attended 
influenza infection) may be missed if influenza was not 
diagnosed or suspected. To account for this uncertainty, 
two influenza definitions were used to estimate the annual 
incidence for all age groups. The broad influenza-like illness 
definition gave more favorable results, but QIV was esti-
mated to be cost saving in the older adult age group, even 
when using the narrow definition.
Another limitation was that the herd impacts of influ-
enza vaccination were not considered in the model. The 
preferred approach to modeling the economic impact of 
vaccines against infectious diseases (particularly influenza) 
is the use of dynamic models as they incorporate the indirect 
effects of the vaccination. Dynamic modeling approaches 
in France [50], the UK [51], and Germany [52] have shown 
that extending influenza vaccination to younger age groups 
(albeit using the live-attenuated influenza vaccine) would 
result in a significant reduction in morbidity and mortality 
in all other age groups. In France, a 50% coverage of live-
attenuated influenza vaccine in children 2–17 years of age 
was expected to result in a further 28% decrease in cases in 
those over 18 years of age [50]. Similarly, in a German set-
ting, 60% of the additional hospitalizations prevented from 
live-attenuated influenza vaccine use (at 50% coverage) in 
the same age group (2–17 years) were estimated to be from 
those over 18 years of age [52]. Static population models 
do not allow for the inclusion of herd impact, but, owing 
to the simplicity of local data requirements, they may be a 
useful approach where granular local data are limited [53]. 
However, an exploratory analysis subsequently conducted by 
varying the indirect effects in the population over 5 years of 
age by vaccinating the 6–59 months age group alone showed 
that a 4.5% indirect effect in preventing influenza in the non-
vaccinated age group would result in QIV being cost effec-
tive relative to TIV in children (electronic supplementary 
Fig. 10). Nonetheless, because of the incremental nature of 
the base-case analysis, and the fact that QIV was expected to 
be at least as effective as TIV against influenza, the lack of 
inclusion of indirect effects should result in a conservative 
result for QIV [53, 54].
The productivity gains from a switch to QIV were not 
included in this analysis. Even though the two age groups 
(children ≤ 59 months and older adults ≥ 65 years) have 
little or no employment, an episode of influenza is expected 
to result in some productivity loss for a parent (in the case of 
a child) or a caregiver. The inclusion of productivity losses 
should result in an increased estimate of the value of QIV 
over TIV.
Lastly, improvements in the quality of care and reduced 
strain on the healthcare system could be expected from a 
reduction of healthcare resources sought during the peak 
winter periods of an influenza season; these indirect effects 
were not included in the analysis.
Despite these limitations, the results of the current analy-
sis (i.e. a switch from TIV to QIV is expected to be cost 
effective) are concordant with the global body of evidence 
[39, 51, 55–61].
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5  Conclusions
QIV use is expected to lead to increased public health 
improvements over TIV use in the 6–59  months and 
≥ 65 years age groups using both a narrow and broad defi-
nition of influenza. In children aged 6–59 months, a switch 
to QIV is expected to be cost saving using the broad defini-
tion, but not cost effective using the narrow definition due 
to the lack of mortality assumed in the age group and the 
non-inclusion of indirect protection. However, QIV was esti-
mated to be cost saving in the ≥ 65 years age group irrespec-
tive of the influenza definition used, highlighting its value 
in this risk group.
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